Literature DB >> 12750036

How to correct the QT interval for the effects of heart rate in clinical studies.

Patrick Davey1.   

Abstract

Much inter- and intra-subject variability in the QT interval in health and disease is accounted for by differences in heart rate, leading to difficulties when determining the effects of disease and drugs on the QT interval. Traditionally, heart rate correction formulae have been used to overcome this problem in man. However, the commonly used Bazett's heart rate correction formulae (QT=QT(C) radical RR interval) does not remove the effect of heart rate; indeed, it overcorrects at high heart rates. Fredericia's formula (QT=QT(C)x(3) radical RR interval) does remove the effects of heart rate; this is the preferable formula, if one is to be used. However, all formulae make assumptions about the nature of the QT-heart rate relationship, assumptions that may not apply to those with disease or on drugs. A more intellectually rigorous approach to QT interval-heart rate correction is to determine the QT-heart relationship for each individual, using data obtained from exercise tests or 24-h Holter tapes. The best mathematical relationship (linear, exponential, etc.) is obtained from analysis of this data, and is used to determine the QT interval at a heart rate of 60 bpm, the QT(60). The QT(60) measure makes no assumptions about the nature of the QT interval-heart rate relationship, removes the dependence of QT interval on heart rate, and maintains genuine biological differences in the QT interval. It should become the standard in QT interval-heart rate correction.

Entities:  

Mesh:

Year:  2002        PMID: 12750036     DOI: 10.1016/S1056-8719(03)00008-X

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  22 in total

1.  Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation.

Authors:  Julian Puppe; Deborah van Ooyen; Jeanne Neise; Fabinshy Thangarajah; Christian Eichler; Stefan Krämer; Roman Pfister; Peter Mallmann; Marina Wirtz; Guido Michels
Journal:  Breast Care (Basel)       Date:  2017-01-18       Impact factor: 2.860

2.  A novel method for patient-specific QTc--modeling QT-RR hysteresis.

Authors:  David M Hadley; Victor F Froelicher; Paul J Wang
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-01       Impact factor: 1.468

Review 3.  Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice.

Authors:  Geoffrey K Isbister; Colin B Page
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

4.  Is prolonged QTc sufficient to predict survival in patients with intracerebral hemorrhage?

Authors:  Yavuzer Koza
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-02-18       Impact factor: 1.468

5.  Ventricular repolarisation during exercise challenge occurring late after Kawasaki disease.

Authors:  Hugo Gravel; Nagib Dahdah; Anne Fournier; Marie-Ève Mathieu; Daniel Curnier
Journal:  Pediatr Cardiol       Date:  2012-02-18       Impact factor: 1.655

6.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

7.  QTc Prolongation after Ventricular Septal Defect Repair in Infants.

Authors:  Chang Woo Han; Saet Byul Woo; Jae Young Choi; Jo Won Jung; Yong Hwan Park; Han Ki Park; Hong Ju Shin; Nam Kyun Kim
Journal:  Korean Circ J       Date:  2013-12-20       Impact factor: 3.243

8.  Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.

Authors:  Sylvain Goutelle; Elodie Sidolle; Michel Ducher; Jacques Caron; Quadiri Timour; Patrice Nony; Aurore Gouraud
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

9.  Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.

Authors:  Eline Vandael; Thomas Marynissen; Johan Reyntens; Isabel Spriet; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2014-05-08

10.  Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.

Authors:  Eline Vandael; Bert Vandenberk; Joris Vandenberghe; Isabel Spriet; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2016-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.